GENE ONLINE|News &
Opinion
Blog

2020-12-18| In-DepthSpecial

Coexistence of Thrombophilic Factors and Hemophilia – A Blessing in Disguise?

by GeneOnline
Share To
The most common treatment for hemophilia is a factor replacement therapy, but it comes with challenges like frequent infusions, cost, development of inhibitors, etc. To overcome these limitations, new approaches were explored, such as factors with an extended half-life, inhibition of anticoagulant proteins, and gene therapy.
In normal circumstances, the coexistence of two disorders would enhance distress in an already suffering individual, but what would happen if thrombophilia and hemophilia coexist in an individual? Will they complement each other?

GO Prime with only $1.49 now

LATEST
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
Scientists Identify New Genetic Variant Related to Obesity
2022-12-01
Micronbrane Medical Aspires to Further Clinical Collaboration Following the Successful Series A Funding
2022-12-01
FDA Revokes Authorization Of Eli Lilly’s COVID-19 Antibody
2022-12-01
Eisai Unveils Lecanemab Data Following Reports of Second Alzheimer’s Patient Death
2022-11-30
New CRISPR/Cas9 license agreement for ERS Genomics and Cosmo Bio
2022-11-30
Gland Pharma Dispels Rumors Of Fosun Sale, Acquires Cenexi In Separate Development
2022-11-30
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!